The Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

The FDA is recommending an additional clinical trial to confirm glepaglutide’s efficacy and safety at the to-be-marketed dose.

The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.

CBD did not meet primary end point comparing preingestion to postingestion anxiety, but resulted in lower anxiety levels ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

From 2013 to 2022, there was an increase in the percentage of annual emergency department visits with an influenza test ordered or provided, from 2.5% to 10.9%. (HealthDay News) — The use of ...

Concentrations of 3 to 12 and 12 to 35 μg/mL (about three to 12 and 12 to 35 glasses/month of wine) were associated with lower CVD risk. (HealthDay News) — Light-to-moderate consumption of wine ...